Stock Market & Financial Investment News

News Breaks January 29, 2013 06:06 EDT IMUC ImmunoCellular allows IND for ICT-140 ImmunoCellular Therapeutics announced that the FDA has allowed the investigational new drug, or IND, application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells. ImmunoCellular filed the IND application with the FDA in the Q4 of FY12, as planned. News For IMUC From The Last 14 Days Check below for free stories on IMUC the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 16, 2013 06:02 EDT IMUC ImmunoCellular announces issuance of key patent covering cancer vaccine target Subscribe for More Information May 9, 2013 16:02 EDT IMUC ImmunoCellular reports Q1 EPS (10c), consensus (8c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.